Immunoprecise Historical Cash Flow
| IPA Stock | USD 0.38 0.02 5.00% |
Analysis of Immunoprecise Antibodies cash flow over time is an excellent tool to project Immunoprecise Antibodies future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 2.5 M or Depreciation of 6 M as it is a great indicator of Immunoprecise Antibodies ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Immunoprecise Antibodies latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunoprecise Antibodies is a good buy for the upcoming year.
Immunoprecise |
About Immunoprecise Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Immunoprecise balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Immunoprecise's non-liquid assets can be easily converted into cash.
Immunoprecise Antibodies Cash Flow Chart
Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Immunoprecise Antibodies financial statement analysis. It represents the amount of money remaining after all of Immunoprecise Antibodies operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Most accounts from Immunoprecise Antibodies' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Immunoprecise Antibodies current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.At present, Immunoprecise Antibodies' Change In Working Capital is projected to increase significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 8.8 M, whereas Change In Cash is projected to grow to (4.6 M).
Immunoprecise Antibodies cash flow statement Correlations
Click cells to compare fundamentals
Immunoprecise Antibodies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunoprecise Antibodies cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (2.8M) | 39.1M | (11.8M) | (21.7M) | (4.8M) | (4.6M) | |
| Free Cash Flow | (2.0M) | (2.0M) | (11.2M) | (21.3M) | (5.6M) | (5.4M) | |
| Change In Working Capital | (1.1M) | (1.0M) | 582K | (3.3M) | 2.4M | 2.5M | |
| Begin Period Cash Flow | 5.5M | 2.7M | 41.8M | 30.0M | 8.4M | 8.8M | |
| Other Cashflows From Financing Activities | 596.6K | (2.5M) | (5K) | (2.0M) | 2.4M | 2.5M | |
| Depreciation | 3.4M | 3.7M | 3.8M | 6.7M | 5.7M | 6.0M | |
| Other Non Cash Items | 982.1K | 1.4M | (310K) | 2.3M | 15.1M | 15.8M | |
| Capital Expenditures | 575.6K | 1.4M | 1.3M | 1.5M | 1.4M | 1.5M | |
| Total Cash From Operating Activities | (1.4M) | (600K) | (9.9M) | (19.8M) | (4.2M) | (4.0M) | |
| Net Income | (4.9M) | (7.3M) | (16.7M) | (26.6M) | (27.2M) | (25.8M) | |
| Total Cash From Financing Activities | 174.7K | 43.4M | 2.9M | (621K) | 1.0M | 970.0K | |
| End Period Cash Flow | 2.7M | 41.8M | 30.0M | 8.4M | 3.5M | 4.1M | |
| Stock Based Compensation | 739K | 2.7M | 3.1M | 1.9M | 1.5M | 1.3M | |
| Change To Account Receivables | (933.3K) | (439K) | 163K | (561K) | (601K) | (571.0K) | |
| Change To Inventory | (23.4K) | (316K) | (501K) | (185K) | (102K) | (107.1K) | |
| Investments | (1.6M) | (2.5M) | (5.2M) | (2.0M) | (1.6M) | (1.6M) | |
| Net Borrowings | (318.5K) | (772K) | (962K) | (1.3M) | (1.2M) | (1.1M) | |
| Total Cashflows From Investing Activities | (1.6M) | (2.5M) | (5.2M) | (2.0M) | (1.8M) | (1.9M) | |
| Change To Operating Activities | (192.9K) | (1.3M) | (620K) | (806K) | (725.4K) | (761.7K) | |
| Change To Netincome | 1.3M | 4.0M | 2.4M | 3.3M | 3.8M | 2.9M | |
| Change To Liabilities | 922.1K | 624K | 1.4M | (1.7M) | (1.6M) | (1.5M) | |
| Issuance Of Capital Stock | 493.2K | 44.2M | 3.9M | 716K | 2.4M | 2.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.76) | Revenue Per Share 0.921 | Quarterly Revenue Growth (0.07) | Return On Assets (0.13) | Return On Equity (0.64) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.